Japan Business Unit

Initiatives for 5-year Business Plan

In Japan, we have earned the trust of medical professionals in the primary care field by providing therapeutic agents for a wide range of diseases, including cardiovascular diseases such as thromboembolism, lifestyle-related diseases, diseases related to the central nervous system, and diseases related to pain. Under the current 5-year business plan, we aim to become the most trusted healthcare partner in the oncology field by focusing on *Enhertu*®, which we launched in May 2020. In addition to creating efficacy and safety information related to cancer therapy, we are going to deliver information with sincerity from the perspective of total patient-centered care. And we are always exploring ways to contribute to the medical community as members of comprehensive business that offering our many primary care products, oncology products, vaccines, and generic drugs.

Furthermore, as a strong partner to healthcare professionals in Japan, our goal is to be the best company in Japan, both in name and reality, capable of accurately responding to all needs, from prevention to treatment and in reducing healthcare costs.

FY2021 Major Results

In FY2021, new organization, "Japan Business Unit," has started to increase our contribution to patients at the level of No. 1 in Japan by the effective collaboration among Medical Affairs (MA), Marketing, and Sales functions and by use of our strengths in the primary market to grow in the oncology market.

April 2021, we launched *Emgality*®, a migraine attack suppressant with a new mechanism of action. We were able to provide a new treatment option for patients that suffer from migraines. *Enhertu* is now in its second year on the market, and by continuing to focus on safety and ensuring that it is used appropriately by patients, *Enhertu* has grown to capture the top market share in both the breast and gastric cancer fields.

In FY2021, we maintained our No. 1 rating in MA activities (cardiovascular field), MR activities, and inquiry response in a survey of healthcare professionals conducted by an external organization.

Shoji Hirashima

Head of Japan Business Unit

Shoji Hirashima joined the company in 1988. He worked in R&D, Global Marketing, and planning of the 5-year business plan as CEO of U3 Pharma GmbH, Head of Global Brand Strategy Division, and Head of Corporate Strategy Division. He was appointed to his current position as Head of Japan Business Unit in April 2022. In June 2022, he was appointed Representative Director and Senior Executive Officer.

Oncology Business Unit

Initiatives for the 5-year Business Plan

The Oncology Business Unit (OBU) will contribute to our current 5-year business plan by maximizing our antibody-drug conjugates (ADCs), changing the standard of care for cancers such as certain breast and lung cancers, and establishing Daiichi Sankyo as a global oncology leader.

The OBU's paramount responsibility is to ensure our medicines reach the right patients, at the right time, in the U.S. and European markets. We collaborate with the healthcare community, market access decision-makers, and patient advocacy groups to provide them with the information they need about our medicines in order to make the best treatment decisions for patients.

FY2021 Major Results

The OBU, established in April 2021, is now a highly collaborative, accountable, and agile organization working as one unified team seeking to transform the oncology landscape through medicines that change the standard of care. We entered year two having increased revenue from the OBU by nearly 46.9%, reaching ¥69.6 billion. This contribution is primarily due to sales of *Enhertu* (fam-trastuzumab deruxtecan-nxki) in the U.S. and Europe, as well as strong sales of TURALIO™ (pexidartinib) in the U.S. Our team successfully launched *Enhertu* in the U.S. and Europe in 2021 for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who received two or more prior anti-HER2-based regimens in the metastatic setting, while preparing for additional launches in FY2022. The OBU is proud to have significantly contributed to *Injectafer* (ferric carboxymaltose injection) enjoying its strongest quarterly performance since its launch in 2013 as a result of our continued co-promotion with our affiliate, American Regent. Demand was driven by accurate and compelling communications and engagement with our customers regarding our products' strong clinical profiles.

As we prepare for multiple launches over the coming years, we have established a world-class launch excellence platform enabling continuous learning. We attracted and developed talent and formed global and regional leadership teams of experts in the fields of medical care, marketplace dynamics, patient access, and more. What drives us is a deep sense of responsibility to patients and to each other.

Ken Keller

Head of Oncology Business Unit

Ken Keller has more than 30 years of general management, commercial, and joint venture leadership experience in therapeutic areas such as oncology, bone health, inflammation, and primary care. Prior to Daiichi Sankyo, Ken led successful, high-profile business units in the U.S. and Europe at other innovative healthcare companies.

EU Specialty Business Unit

Initiatives for the 5-year Business Plan

We care for every heartbeat. Our goal is to protect people from cardiovascular disease and help those who suffer from it, so they can enjoy every precious moment that life has to offer. For us care goes beyond providing medicines. We seek to understand the needs of patients, caregivers, and healthcare professionals to inform everything we do. Through the strategic use of digital technology and advanced analytics, we create a deep understanding of how we can become better every day at supporting our customers to make the best decisions for patients and explore ways to complement and expand CV care to improve health outcomes. Our Specialty organization is fully focused on delivering outstanding customer experience and living a truly patient centric mindset.

Another important element is our contribution to the sustainable development of society. One focus area is reducing our environmental impact. Another one is our efforts around Inclusion & Diversity to ensure that everybody can bring their best to the table to deliver value to patients and play an active role in shaping our One DS Culture. Our major challenge going forward is the current geopolitical uncertainty and economical volatility, and its possible impact on our business.

FY2021 Major Results

We focus on maximizing *Lixiana*® and growing *Nilemdo*® / *Nustendi*®. *Lixiana* shows a steady growth in most countries with increasing market shares. We also launched *Nilemdo* / *Nustendi* successfully in further European countries. For the first time in our history as Daiichi Sankyo in Europe we were able to reach a revenue of €1 billion. This is the success of our talented and engaged teams all over Europe.

Jan Van Ruymbeke

Head of EU Specialty Business Unit

Jan joined Daiichi Sankyo Europe GmbH in 2012 as Managing Director, CEO. A medical doctor by education, Jan joined the pharmaceutical industry in 1989. After positions as General Manager at Janssen-Cilag Hungary and Country President at Novartis South Africa, from 2005 to 2012 he was Grunenthal's General Manager for Spain and Iberia and Head of Latin America. Throughout his career Jan has been focusing on creating customer centric organizations.

ASCA Business Unit

Initiatives for the 5-year Business Plan

The ASCA Business Unit is responsible for the Asia and South & Central America regions. The Unit manages the operations of seven local affiliates in China, Taiwan, Korea, Thailand, Vietnam, Hong Kong, and Brazil, providing support for marketing activities, medical affairs activities, market access and pricing activities, and export businesses of our partners. Under the banner of "One ASCA," which combines our existing business and oncology business, we aim to secure high profitability and build a foundation to transform into an oncology business by 2025. Our 2030 Vision is to "deliver our products faster and to more patients in ASCA region. Focusing on the oncology business and showing presence in each country/region."

We plan to enhance our business in China, launch our ADC franchise promptly, and expand our business in Australia and Singapore in order to strengthen our sustainable business foundation.

FY2021 Major Results

China, which has a large number of patients, is expanding the application of its volume-based procurement (VBP) program as a drug price control measure. In order to efficiently invest management resources of local affiliates, we reviewed our sales organization structure in China, expanded sales channels for VBP- items through new channels, and spun off the CRAVIT business. Our growth driver, *Lixiana*, maintained its top market share in South Korea and the second largest in Taiwan, and is steadily increasing its presence across all the regions we serve. In April 2021, we reached an agreement with Esperion to negotiate the in-licensing of bempedoic acid, a drug for hypercholesterolemia, and will begin full preparations for its launch in South Korea, Brazil, Taiwan, Hong Kong, Macau, Thailand, Vietnam, Myanmar and Cambodia.

For *Enhertu*, we contributed to providing early access to medical care by launching the Early Access Program (Importation Program) in Hong Kong, China, and Taiwan. In addition, we obtained approval and began marketing in Brazil, Hong Kong, and Taiwan. We will continue to do our utmost to deliver our products promptly to as many patients as possible.

Kiminori Nagao

Head of ASCA Business Unit

Kiminori Nagao has been engaged in the development of new drugs since joining the company in 1988. In his previous position as the Head of Development Division in Japan, he promoted development of new drugs globally, including in Japan and Asia. For two years from 2014, he was the Head of Clinical Development and Regulatory Affairs in Asian countries excluding Japan. He assumed his current role in April 2021.

American Regent Unit

Initiatives for the 5-year Business Plan

American Regent strives to continue to supply and deliver superior quality products that healthcare providers rely on for their patients while focusing on fulfilling unmet needs in healthcare by providing industry leading US manufactured Sterile Injectables. To support the needs of the current 5-year business plan, American Regent will grow through development of our product pipeline, expanded indications/patient population of existing product and M&A activity. In the coming years, we will look to take advantage of our simplified supply chain and our Capex investment in on-shore manufacturing.

FY2021 Major Result

The COVID-19 pandemic created worldwide supply chain challenges and disruption of supply. With proactive planning, advanced ordering and increasing inventory levels of needed materials, American Regent was able to meet and exceed all financial targets by supplying medically necessary drug products. Much of our success was came from meeting market demand created by supply interruptions of other manufactures. Revenue targets were exceeded in our three major categories. *Injectafer* achieved ¥53.1billion. *Venofer* achieved ¥33.8 billion. Generic injectables achieved ¥54.7 billion.

Paul Diolosa

Head of American Regent Unit

Prior to joining American Regent, Paul served as Director of Engineering at Altana Pharmaceuticals for 10 years. His leadership in modernizing manufacturing operations led to promotions of increasing responsibility since he joined the company in 2008. He has spent the past 13 years committed to implementing significant investments in the company's facilities, equipment, people, and practices, including a state-of-the-art manufacturing expansion with a capacity to help millions of patients. He assumed the role of President and CEO of American Regent, Inc. in April 2021.

Daiichi Sankyo Healthcare Unit

Initiatives for the 5-year Business Plan

To achieve sustainable growth, Daiichi Sankyo Healthcare Unit is driving the following market strategies with the goal of reaching ¥100 billion in revenue in the 5-year business plan toward 2025.

1. Domestic in-store sales business: Strive to capture the top share in our target OTC markets (excluding tonic drinks) and expand our core brands in the functional skincare and oral care markets.
2. Mail-order business: Expand skincare business and strengthen development in the lifestyle improvement field
3. Overseas business: Accelerate growth in our China business by collaborating with cross-border Electronic Commerce (EC) companies and strengthening our product lineup.

With regard to the environment surrounding us as we strengthen our existing businesses, consumers are becoming increasingly conscious of their health as "self-care" and "self-medication" has become widespread, as part of efforts to prevent disease, improve health, and extend their healthy lifespans.

In response to these trends, we are focusing on developing products that meet the diverse needs of consumers to be healthy and beautiful, with the aim of achieving sustained growth.

FY2021 Major Results

Although the outlook remains uncertain due to continued slump in consumption stemming by the COVID-19 pandemic, we have been actively engaged in marketing activities by developing new products with an eye on new lifestyles and optimizing the allocation of investment to growing brands. In addition, we strived to revitalize the market by further strengthening information delivery and in-store promotion activities that reflect changes in consumption trends triggered by the pandemic.

As a result, our growth surpassed that of the OTC market YoY, and we are in a position to capture the top share in our target OTC markets (excluding tonic drinks).

In addition, outside of our existing businesses, we have launched the Sleep Consortium initiative as a new business incorporating DX to realize our 2030 Vision, and we are planning to start a business selling sleep assessments to other companies in the future.

Katsuhiko Yoshida

Head of Daiichi Sankyo Healthcare Unit

Katsuhiko Yoshida joined Daiichi Sankyo Healthcare Co., Ltd. on April 1, 2007, after working in corporate strategy for many years.
He served as Director, Senior Executive Officer and Vice President of Corporate Strategy Division before assuming the position of President and Representative Director (Head of Daiichi Sankyo Healthcare Business Unit) in April 2019.

Research & Development Unit

Initiatives for the 5-year Business Plan

The current mission of the R&D Unit is to continue strengthening our global research and development capabilities and maximizing the value of our oncology pipeline, particularly our 3ADCs. We will deliver assets based on our strength in ADC technology, with promising targets such as HER2 and TROP2, to patients around the world. We also will continue to accelerate research and development of our superior oncology pipeline including the rest of the DXd-ADC family and the next generation ADCs, and explore new modalities in both the oncology and specialty medicine therapeutic areas.

We also innovate in central nervous system (CNS) and rare disease areas with high unmet medical needs, leveraging our unique R&D capabilities, advanced technologies, and precision medicine - to revolutionize the standard of care.

FY2021 Major Results

In FY2021, the R&D Unit achieved many milestones through the efforts of R&D members and through collaborations with Daiichi Sankyo RD Novare and external global partners. We achieved outstanding results with our 3ADCs. The DESTINY-Breast03 and DESTINY-Breast04 study results for *Enhertu* are expected to dramatically change the standard of care in some cancers. We also achieved great progress with the "Rising Stars" in the DXd-ADC family and in strengthening the modality technology and research intended to support further growth of the pipeline, as well as progress in the development of *DS-5670*, a COVID-19 vaccine. And we also launched products such as *Edoxaban*. In addition we achieved important milestones in the Alpha oncology and specialty medicine projects and advanced research programs, and implemented organizational and capability enhancements to realize the Global RD One Team approach.

We are focusing on new and sustainable ways of working to ensure that all in the R&D Unit can contribute to our Purpose and Mission, to deliver our innovative and important Science & Technology to patients around the world.

Ken Takeshita

Head of Research & Development Unit

Ken Takeshita was engaged in research at the University of Tokyo and other universities after earning a bachelor's degree in molecular biology from Harvard University and his medical degree from Yale University. He then joined the pharmaceutical industry and led drug development programs including anti-cancer drugs at several global pharmaceutical companies. He served as Global Head of Development as well as interim Head of Research at Kite Pharma since 2019. He was appointed as Daiichi Sankyo's Global Head of R&D as of April 2021.

Biologics Unit

Initiatives for the 5-year Business Plan

In the current 5-year business plan, the Biologics Unit aims to maximize the value of Daiichi Sankyo's ADCs while enhancing its own antibody technologies, with the goal of becoming a technology unit that maximizes the value of ADCs and creates Beyond ADCs with cutting-edge biotechnologies. Furthermore, our 2030 Vision is to become a "technology unit which transforms medical modalities through antibody, cell, and gene engineering technologies." In line with this, we are developing not only technology for antibody pharmaceuticals, but also the fundamental and production technologies necessary to create innovative pharmaceuticals based on cells and genes, which are expected to become next-generation modalities.

FY2021 Major Results

In FY2021, we provided support for antibody manufacturing technologies in the manufacturing division to prepare for future increase in demand for antibodies used in 3ADCs. In addition, we have established antibody production methods for Dxd-ADCs following 3ADCs, and supplied the antibodies for clinical trials as planned. As for proprietary technology development, we have developed manufacturing technology for the practical application of CHO-MK, a new cell line produced in-house with excellent antibody production activity, proliferation speed, and stability in culture, in order to apply this cell line to antibody pharmaceuticals in the future. We have also established manufacturing methods for antibodies to be used in next-generation ADCs and new-concept ADCs that will follow Dxd-ADCs.

In the areas of regenerative medicine and cell therapy, we provided technical support for the commercial production of *Yescarta*® intravenous drip infusion and support for obtaining approval of *Delytact*® injection, which led to the launch and production of our regenerative medicine products. For mRNA vaccines, while promoting the COVID-19 project (*DS-5670*), we explored antigen designs for various mutant strains of the new coronavirus and established a mass production method for mRNA. Furthermore, we established a manufacturing method for adeno-associated virus (AAV) for gene therapy introduced from Ultragenyx Pharmaceutical Inc. in-house, and created the foundation and production technology for next-generation modalities.

Masayuki Yabuta

Head of Biologics Unit

Masayuki Yabuta joined Pharmaceutical Division of Suntory Ltd. in 1985. He was engaged in the research of manufacturing methods and construction of manufacturing facilities for recombinant proteins and peptides, and accumulated experience in the development of manufacturing methods for many biopharmaceuticals. In 2010, he joined Daiichi Sankyo, where he worked in the Pharmaceutical Technology Division and R&D Division before assuming his current position in 2017 with the establishment of the Biologics Unit.

Pharmaceutical Technology Unit

Initiatives for the 5-year Business Plan

The mission of the Pharmaceutical Technology Unit is to leverage advanced pharmaceutical technologies to enhance the value of pharmaceuticals discovered through R&D and deliver them to patients. Over the course of the current 5-year business plan, we aim to maximize value of 3ADCs in parallel with rapid development of Alpha assets by steadily transferring our technologies to a number of CDMOs, ensuring the supply of investigational drugs to each country and region, submitting applications for approval and change control in countries and regions where we are not experienced in, and also designing high quality and user-friendly pharmaceuticals. As part of this effort, we will quickly develop new technologies for various modalities. We will take on the challenge of establishing the pharmaceutical technologies and CMC regulatory strategies needed for a variety of inexperienced modalities such as next-generation antibodies/ADCs, LNP-mRNA, and gene therapy, by fully leveraging the knowledge and experience we have accumulated through small molecule and DXd-ADC development.

Furthermore, in response to globalization of our stakeholders, we will strive to maximize our global organization capability by enhancing individuals' strength (embracing diversity) through developing human resource and improving way of working.

FY2021 Major Results

In the Pharmaceutical Technology Unit, we steadily expanded the number of countries where *Enhertu* is marketed and added production sites to ensure a stable supply. At the same time, we worked to provide a flexible supply of investigational drugs in accordance with clinical plans, established robust commercial manufacturing methods, and transferred technologies to numerous production sites to support the rapid development of *Dato-DXd*, *HER3-DXd*, and Alpha assets. Furthermore, in terms of COVID-19 vaccine response, which has become a pressing social issue, we contributed to improving healthcare both in Japan and abroad by enabling shipments of VAXZEVRIA™ (AstraZeneca's COVID-19 vaccine) to Asia through providing support for the technology transfer to production site in Japan and through supporting CMC regulatory activities. In addition, we advanced the development of production technology for the first Japanese LNP-mRNA vaccine (*DS-5670*) at an unprecedented pace.

Moreover, we have contributed to ESG management by promoting green chemistry and exploring the application of biomass plastic for packaging materials.

Toshi Kajiro

Head of Pharmaceutical Technology Unit

Toshi Kajiro joined Sankyo Co., Ltd. in 1992 and worked in analytical evaluation research for 24 years, focusing on small molecules. She spent two years in the CMC Planning Department, where she was involved in unit operations and strategy development. In 2018, she became Senior Director of research group for biopharmaceuticals under the Analytical & Quality Evaluation Research Laboratories and contributed to obtaining approval for *Enhertu*. She was appointed as Vice President of Analytical & Quality Evaluation Research Laboratories in April 2020, and assumed her current position in April 2022.

Supply Chain Unit

Initiatives for the 5-year Business Plan

Under our 2030 Unit Vision to "contribute to maximizing the value of ADC products and to realize Smart Supply Chain" we are working on the following key challanges. First, we are establishing an optimal supply system for the antibody, bio drug substance, drug formulation, and packaging processes by leveraging our plants and CMOs to ensure a stable supply of ADC products and expand our supply capacity. Then, for new modalities that will follow the ADCs, we will optimize our supply system by selecting commercial manufacturing sites in the development phase, taking into consideration our manufacturing technologies and resources as well as the option of using CMOs.

Meanwhile, as part of our digital transformation initiatives, we are actively introducing digital technologies in supply and demand management, manufacturing, and logistics with the aim of ensuring stable supply, improving quality and productivity, strengthening human resource development, and streamlining business operations. Furthermore, we will strengthen supply chain resilience to enable continuous supply of pharmaceuticals in the event of natural disasters, a pandemic, or other risks that may materialize.

FY2021 Major Results

In addition to ensuring a stable supply of *Enhertu* in line with the market launch and sales progress in each country, we pushed forward with establishing new facilities to meet the future increase in demand and developing a production system for the DXd-ADC family under development. As for new modalities, we also proceeded with preparations for the production of *DS-5670* (mRNA vaccine) at Daiichi Sankyo Biotech with the aim of launching it by the end of 2022.

Meanwhile, in terms of digital transformation initiatives, we created a Digital Transformation Promotion Roadmap for introducing digital technologies into the manufacturing and logistics. In addition, we proceeded with the introduction of a new supply-demand management system that shares production, sales, and inventory information for Enhertu across all countries in real time. Furthermore, in the face of rising raw material prices and production disruptions and delivery delays at suppliers caused by the COVID-19 pandemic, we worked to stabilize procurement while also strengthening our supply chain resilience by multi sourcing and alternative purchasing for raw materials and consumables for manufacturing with high procurement risk.

Hiroto Kashiwase

Head of Supply Chain Unit

Hiroto Kashiwase joined Sankyo Co., Ltd. in 1989 and engaged in exploratory research of antiviral agents for 12 years. After working in corporate strategy and management, he contributed to the merging into Daiichi Sankyo. Following the merger, he worked in the Pharmaceutical Technology Division, managed the US organization, and served as the Head of Pharmaceutical Technology Division before assuming his current position in April 2022.

Quality Assurance & Regulatory Affairs Unit

Initiatives for the 5-year Business Plan

Our oncology business is undergoing rapid expansion with the acceleration of global development of 3ADCs and other products. The Quality Assurance & Regulatory Affairs Unit will steadily implement measures to (1) assure the reliability of many clinical trials to maximize product value by adding new indications, (2) respond to regulatory filings and approvals and assure product quality to expand markets in more countries/regions and supply capacity, and (3) ensure the reliability of the management system for safety information, which is important in the oncology field.

In addition, we will develop a reliability assurance system for our first two regenerative medical products, mRNA vaccines and other new modalities, and extend this further to include DTx (digital therapy) and other diverse healthcare solutions in the future.

As we navigate these changes in the business environment, we will continue to develop measures to foster a quality culture throughout the entire Group, based on our fundamental principle of "Quality First."

FY2021 Major Results

We promoted measures to start production and ensure quality at new manufacturing sites handling 3ADCs as planned. In particular, for *Enhertu*, we completed the requirements for GMP certification in the U.S. and other countries and regions in a timely manner, which contributed secure approvals in these countries. In response to the addition of new manufacturing sites and changes in manufacturing processes, we took appropriate quality assurance measures and meticulously complied with different regulatory requirements in each country and region, contributing to the stable supply of products. In addition, we have implemented measures to comply with GCP regulations in various clinical trials, and have successfully completed the rigorous GCP inspections by the authorities.

With regard to the *Delytact* injection, a regenerative medicine product, we promptly completed the GCTP inspection of the manufacturing site and contributed to the early launch of the product.

In addition, we contributed to the smooth launch of new products by handling GMP inspections and implementing quality assurance measures, and obtained approval for additional drug substance manufacturing sites as planned to ensure a stable global supply of our existing mainstay products.

For existing MAH products in Japan, we actively worked to improve customer satisfaction and achieved a substantial reduction in quality complaints caused by manufacturing process (45% reduction from the previous fiscal year).

Toshinobu Taki

Head of Quality Assurance & Regulatory Affairs Unit

Toshinobu Taki joined the company in 1987 and started his career as a plant quality assurance. After gaining experience in quality assurance for both marketed and investigational medicinal products and in CMC management, he was appointed as the Vice President of Quality Assurance Department in 2017 and the Vice President of Post-Marketing Regulatory Affairs Department in 2019. He assumed his current position in April 2022.

Clinical Safety & Pharmacovigilance Unit

Initiatives for the 5-year Business Plan

A medicinal product must have a high level of quality combined with the provision of appropriate information. Also, even if it is highly effective, no medicinal product comes available without the risk of side effects.

Under the current 5-year business plan, we have been promoting R&D for new modalities, while working on the global expansion of oncology drugs. Along with such initiatives, an increase in the amount of safety information and the diversity and complexity of risk management issues are already occurring.

In the Clinical Safety & Pharmacovigilance Unit, we have set three main targets as part of the 5-year business plan, consisting of establishing high-quality safety risk management, streamlining operational processes, and strengthening global systems and functions.

FY2021 Major Results

In FY2021, the Clinical Safety & Pharmacovigilance Unit worked on the following four targets.

1. Global Risk Management for *Enhertu*

In addition to contributing to the application for approval in each country and region from the safety perspectives and thorough post-marketing risk management, we established and implemented a risk management system to ensure the safe use of *Enhertu* in special treatment programs in Asia countries, where *Enhertu* is not yet approved. Through these activities, we contributed towards expanding access to healthcare for patients.

2. Proactive risk analysis and reinforcement of timely safety measures

By introducing an analytic tool for *Enhertu* that enables easy and comprehensive search and analysis of clinical trial data, we enhanced the analysis function of safety data and enabled timely provision of information.

3. Integrate global process and management of case evaluation

By promoting global integration of the case evaluation process, we have established the foundation for conducting efficient case evaluations.

4. Maintain and strengthen pharmacovigilance infrastructure

We began operating a new global governance system in FY2022.

We will continue to execute proactive safety monitoring and risk management to achieve our 5-year business plan and contribute to ensuring patient safety.

Kento Wada

Head of Clinical Safety & Pharmacovigilance Unit

Kento Wada joined Suntory Limited in 1991 and was responsible for works including new drug development, project management in Japan and the U.S., the launch of subsidiary in the U.S., and business planning. After transferring to Daiichi Sankyo in 2010, he was engaged in global clinical safety and pharmacovigilance. He assumed the Head of Clinical Safety & Pharmacovigilance Division in April 2020 after serving as Vice President, Pharmacovigilance Department and Vice President, Post Marketing Study Department.